Selank Complete Guide: Benefits, Dosing, Side Effects & Research

Introduction

Selank is a synthetic heptapeptide derived from tuftsin, a natural immune modulating fragment of the heavy chain of immunoglobulin G. It was developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences and the V.V. Zakusov Research Institute of Pharmacology. The original goal was to build a peptide anxiolytic without the sedation, dependence, or cognitive blunting of benzodiazepines.

In Russia, selank has been registered as a prescription drug under the trade name Selanc for generalized anxiety disorder. In the United States it has no FDA approval and exists in the same gray market as most research peptides. The pharmacology is more interesting than most underground peptides because selank has been studied in actual clinical trials (small, mostly Russian) and has a plausible mechanism involving GABAergic and serotonergic systems plus immune modulation through interferon and BDNF pathways.

This is the complete guide. It covers the chemistry, the mechanism, what the trial data actually shows, dosing protocols, side effects, drug interactions including with GLP-1 medications, and the practical questions about supply, quality, and legality.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is Selank?

Selank is a seven amino acid synthetic peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues come from tuftsin, a tetrapeptide that occurs naturally in mammalian IgG and has documented immune modulating activity. The C terminal Pro-Gly-Pro tail was added to make the molecule resistant to enzymatic degradation, extending its half life.

Quick Answer: Selank is a synthetic tuftsin analog (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed in Russia for generalized anxiety disorder

The drug was developed by a team led by Lyudmila Andreeva at the Institute of Molecular Genetics, in collaboration with the Zakusov Institute of Pharmacology. It was registered in Russia for generalized anxiety disorder in the early 2000s. The Russian trade name is Selanc. It’s sold there as a 0.15 percent intranasal solution.

In the US it has no FDA approval for any indication. There are no INDs filed for Western development. The compound circulates in the research peptide market and is sometimes available through compounding pharmacies that work outside the standard FDA framework.

How Does Selank Work in the Brain?

Selank acts on multiple targets, which is part of why it’s hard to classify cleanly. The primary documented effects are on the GABA system, where it appears to potentiate GABAergic transmission without binding directly to benzodiazepine sites. Kozlovskii and colleagues (2006, Bull Exp Biol Med) showed that selank increased GABA concentrations in the cortex and hypothalamus of rats.

The second documented mechanism is on serotonin metabolism. Selank increases serotonin turnover in the brain and appears to modulate 5-HT receptors, which would explain part of the anxiolytic effect. The third mechanism involves BDNF (brain derived neurotrophic factor) and the interferon system. Kolomin et al. (2010, Neurosci Behav Physiol) reported that selank altered expression of dozens of genes related to inflammation and neuroplasticity in rat hippocampus.

The clinical pattern is unusual. Benzodiazepines work fast, work strongly, and carry tolerance and dependence. SSRIs take weeks to work and have a long side effect tail. Selank, in the Russian trials, looks more like a rapid acting anxiolytic without the sedation or dependence profile. Whether that holds up in larger Western trials is unknown because those trials don’t exist.

What Does the Russian Anxiety Data Show?

The most cited human study is Zozulia, Neznamov, and colleagues (2008, Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova). They compared intranasal selank to medazepam (a benzodiazepine sold in Russia and Europe) in patients with generalized anxiety disorder. Both reduced anxiety symptoms on the Hamilton Anxiety Rating Scale. Selank produced less sedation, less cognitive impairment, and no withdrawal symptoms on discontinuation.

The sample size was modest (around 70 patients) and the trial was open label by Western standards. There were follow up studies in adjacent indications including neurasthenia and adjustment disorder, mostly from the same Russian research group. The pattern across studies is consistent: modest to moderate anxiolytic effect, minimal sedation, no addictive liability.

For context, sertraline (an SSRI) showed a roughly 50 percent response rate in GAD trials (Allgulander et al. 2004, Br J Psychiatry). The selank effect sizes in the Russian work are in a similar range, though the trials are smaller and less rigorous methodologically.

Is Selank a Nootropic?

People sell it as one but the cognitive data is thinner than the anxiety data. Semenova et al. (2007, Bull Exp Biol Med) reported that selank improved memory consolidation in rats. A few clinical reports describe improved attention and reduced mental fatigue in patients with mild cognitive complaints, but these are case series rather than RCTs.

The mechanism case for cognitive enhancement rests on BDNF upregulation and serotonergic modulation. Both can plausibly support learning and memory. The honest answer is that selank’s nootropic claims are extrapolated from animal data and anecdote rather than confirmed by trials in healthy humans.

What Is the Typical Dosing Protocol?

The Russian registered protocol for Selanc is 300 mcg intranasal three times daily (total 900 mcg per day) for 10 to 14 days. Some clinicians extend the course to 21 days for more severe anxiety. The intranasal route is used because the peptide doesn’t survive oral digestion and because intranasal delivery may allow some direct access to the brain through the olfactory pathway.

In the research peptide community, dosing varies. Common ranges are 250 to 750 mcg per day, split into two or three intranasal doses. Some users inject subcutaneously, which is off label and unstudied. Cycles typically run 10 to 14 days, often repeated every few months rather than continuously.

There is no high dose RCT establishing an upper safe limit. The Russian product label warns against doses above 900 mcg per day but doesn’t cite specific toxicity data.

What Are the Side Effects?

Reported side effects in the Russian literature are minimal. Mild headache, occasional nasal irritation from the intranasal route, transient sleepiness in some patients. No serious adverse events have been reported in the published trials. There’s no signal of dependence or withdrawal even after weeks of dosing.

The honest caveat is that detection of rare adverse events requires large sample post marketing surveillance, which selank has never had in Western pharmacovigilance systems. The Russian product has been on market for two decades with no major safety signals reported, but that’s a low resolution dataset.

There’s no published case of pancreatitis, hepatotoxicity, hematologic abnormality, or major organ toxicity. Drug induced QT prolongation has not been reported. The drug looks safe at standard doses based on existing data, with the acknowledged limitation that the data set is small.

Is Selank Legal in the US?

Selank is not FDA approved for any indication. It’s not a scheduled substance, so possession isn’t criminally illegal at the federal level. Sale of unapproved drugs for human use is illegal, which is why research peptide vendors label everything “not for human use.” Compounding pharmacies in some states will prepare selank if a licensed prescriber orders it, but this exists in a legal gray area because the FDA hasn’t recognized a compounding bulk drug substance approval for selank.

Importation is technically illegal under FDCA but typically not enforced for small quantities purchased for personal use. This is the same gray zone where most research peptides live. None of this is legal advice, just a description of the landscape.

Where Does It Come From on the Market?

The legitimate Russian source is Innovative Pharmaceutical Concepts, the licensed manufacturer of Selanc. That product is dispensed in Russian pharmacies with prescription. It rarely makes it into the US market through legal channels.

The peptide research market is supplied by Chinese contract manufacturers of varying quality. Independent third party analyses of underground peptides have found purity issues, wrong sequences, and bacterial endotoxin contamination across multiple compounds. Selank from gray market sources may or may not be what the label claims. Caveat emptor.

How Does Selank Compare to N-acetyl Semax?

Semax is the other famous Russian neuropeptide, often confused with selank. Semax is an ACTH (4-10) analog originally developed for stroke recovery and now used in Russia for cognitive and attentional indications. Selank is anxiety focused, semax is more cognition focused.

Both are in the same gray market category in the US. Both have small Russian RCTs supporting their use. Neither has Western FDA approval. People sometimes stack them, intranasally, with selank dosed for anxiety and semax dosed for cognitive performance. There’s no head to head trial.

Does Selank Interact with GLP-1 Medications?

There’s no published study of selank combined with semaglutide or tirzepatide. The pharmacology doesn’t suggest a direct interaction. GLP-1 drugs work on glucose and appetite pathways. Selank works on GABA, serotonin, and BDNF. They don’t share receptors or metabolic pathways in any obvious way.

The theoretical concerns are indirect. GLP-1 drugs occasionally cause low mood or anxiety in some patients, and selank could plausibly help with that symptom. Conversely, if selank improves mood and appetite regulation, it could change how strongly the GLP-1 effect is felt subjectively. None of this has been studied.

If you’re on a TrimRx personalized treatment plan with compounded semaglutide or tirzepatide and you’re considering adding selank, the responsible move is to tell your prescriber. The free assessment quiz on the platform focuses on GLP-1 eligibility and doesn’t address peptide stacking.

Key Takeaway: Proposed mechanisms include GABA receptor modulation, serotonin metabolism changes, and upregulation of BDNF and interferon gamma

What Conditions Has Selank Been Studied For?

Beyond GAD, the Russian literature includes small studies in:

The first is adjustment disorder and neurasthenia (overlapping with what Western psychiatry calls adjustment disorder with mixed anxiety or chronic fatigue), where selank showed modest improvements in mood and energy. The second is mild cognitive impairment in older adults, where it improved attention and memory metrics in small samples. The third is post traumatic stress symptoms, where preliminary work suggests possible benefit but the trials are very small.

None of these indications have made it into Western treatment guidelines because the trials haven’t been replicated outside Russia at adequate scale.

What’s the Evidence Quality Compared to FDA Approved Anxiolytics?

For context, sertraline received FDA approval for GAD based on RCTs with thousands of patients across multiple centers. Buspirone, lexapro, duloxetine, and pregabalin all have similar level evidence. The selank evidence base is roughly 200 to 400 patients across all Russian studies combined. That’s enough to justify continued research. It’s not enough to justify confident clinical claims.

This is the consistent pattern with peptides developed inside the Soviet biology system. The work is real, the mechanism papers are publishable, but the scale of clinical evidence doesn’t approach what Western regulators require. That gap explains why these compounds remain in the research peptide market rather than entering mainstream medicine.

Is Selank Worth Trying?

That depends on your risk tolerance and your alternatives. If you have generalized anxiety and you’ve tried first line treatments (CBT, SSRIs) without good response, talking to a prescriber about whatever evidence based options remain (buspirone, pregabalin, etc.) makes more sense than ordering selank online. If you’ve exhausted standard options and you understand that you’re using a drug with thin Western evidence and uncertain supply chain quality, that’s a personal choice to make with informed consent.

The drug is plausibly safe at standard doses. The anxiolytic effect probably exists at a clinically meaningful magnitude based on the Russian data. The unknowns are about long term safety, interaction with other medications, and product quality from gray market sources.

What Is the History of Selank Development?

The Soviet biology system in the 1970s and 1980s invested heavily in peptide pharmacology. The thinking was that small peptides could be developed as drugs with cleaner side effect profiles than the small molecule psychoactive drugs that dominated Western pharmacology. Tuftsin, the parent compound of selank, was identified in the 1970s as a phagocytosis stimulating fragment of IgG and became an early target for synthetic analog development.

Lyudmila Andreeva, working at the Institute of Molecular Genetics in Moscow, led the team that designed and synthesized selank. The key insight was that adding the C terminal Pro-Gly-Pro extension would protect the molecule from proteolytic degradation. The Zakusov Institute of Pharmacology then ran the preclinical and early clinical work, eventually leading to Russian regulatory approval.

The drug was patented in the late 1990s. Production scaled at Russian pharmaceutical facilities. Western pharma never picked up the IP. By the time the patents had aged enough for generic development, the compound was already widely available through research peptide channels and there was no commercial incentive for anyone to run the expensive Western trials.

How Does Selank Fit Into the Broader Peptide Market?

Selank sits in a specific niche. It is not a longevity peptide like epithalon, not a growth hormone secretagogue like CJC-1295 or ipamorelin, not a sexual function peptide like PT-141. It is a neuropsychiatric peptide aimed at anxiety and adjacent mood states. The closest Russian equivalents in market positioning are semax (cognition and stroke recovery), bromantane (anti asthenic, motor activity), and noopept (a different class but similar nootropic positioning).

Each of these compounds has the same general evidence shape. Small Russian trials supporting the headline indication, mechanism papers from Russian academic labs, no Western regulatory development, and a gray market supply chain. People who follow Russian neuropsychopharmacology tend to view selank as one of the stronger compounds in this set, partly because the anxiolytic mechanism is concrete and partly because the safety profile across two decades of Russian post marketing experience looks favorable.

What Labs and Biomarkers Are Worth Checking?

There is no standard lab monitoring protocol for selank because no Western prescribing infrastructure exists. The Russian product label does not call for any specific labs. From a pharmacological standpoint, the conservative approach in a self prescribing context is to check a basic metabolic panel, CBC, and liver enzymes at baseline if you have not had recent labs, and again after a course if you plan to repeat.

For people on GLP-1 therapy through TrimRx or another telehealth platform, those metabolic and hepatic labs are usually part of routine monitoring anyway. There is no specific selank biomarker to follow. Cortisol, BDNF, and inflammatory markers like CRP are theoretically interesting given the proposed mechanism but no reference range exists for evaluating selank response.

Can Selank Help with Sleep?

Indirectly. The Russian anxiety trials reported improved sleep quality as a secondary outcome when baseline insomnia was driven by anxiety. Selank itself is not sedating at standard doses, which is part of its appeal versus benzodiazepines, but if anxiety is preventing sleep, treating the anxiety can improve sleep architecture.

For primary insomnia without anxiety, there is no published evidence selank helps. Better validated options for chronic insomnia include CBT-I (the first line treatment per AASM guidelines), dual orexin receptor antagonists like suvorexant or lemborexant, and ramelteon. These have actual sleep architecture data from randomized trials.

What Is the Storage and Stability Profile?

Selank as a reconstituted solution is reportedly stable for several weeks refrigerated. The intranasal product registered in Russia is shelf stable at controlled room temperature with a typical pharmaceutical shelf life. Research peptide vials are usually shipped lyophilized and require reconstitution with bacteriostatic water before use, then refrigeration.

Anyone using research peptide selank should be aware that reconstitution introduces contamination risk, that bacteriostatic water has its own shelf life after opening (typically 28 days), and that the actual potency of reconstituted research grade peptide tends to drop over weeks of storage. This is part of why the Russian protocol prefers shorter cycles with fresh product rather than open ended daily dosing.

Bottom line: No published interaction data with semaglutide or tirzepatide

FAQ

Does Selank Work for Panic Attacks?

The published research is in generalized anxiety, not panic disorder. There’s no specific data on acute panic. Some users report subjective benefit but this hasn’t been tested.

How Fast Does Selank Work?

The Russian literature describes onset within 30 to 60 minutes of intranasal administration, with full anxiolytic effect after a few days of repeated dosing. This is faster than SSRIs but the comparison isn’t head to head.

Can I Take Selank Daily Long Term?

The registered Russian protocol is 10 to 14 day courses, not continuous use. There’s no long term safety data for daily dosing over months or years. Most clinical experience is with short courses.

Will Selank Show up on a Drug Test?

No. Standard drug screens don’t test for peptides. Selank is not a controlled substance and isn’t part of routine immunoassay panels.

Is Selank Addictive?

No published evidence of dependence or withdrawal. This is one of the cleaner findings in the Russian trials and a major reason it was developed as an alternative to benzodiazepines.

Can Selank Cause Depression?

No signal of induced depression in the trials. If anything, the BDNF and serotonergic mechanisms suggest possible mild mood benefit, though this hasn’t been specifically tested in MDD.

Is Selank Safe with Alcohol?

Not studied directly. Given that selank affects GABA, the theoretical concern is potentiated CNS depression with alcohol, similar to benzodiazepines. The Russian literature doesn’t address this. Better to avoid.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.